Suppression of hepatic tumor growth and metastasis by metronomic therapy in a rat model of hepatocellular carcinoma.
10.3858/emm.2011.43.5.033
- Author:
Jeong Won JANG
1
;
Seong Tae PARK
;
Jung Hyun KWON
;
Chan Ran YOU
;
Jong Young CHOI
;
Chan Kwon JUNG
;
Si Hyun BAE
;
Seung Kew YOON
Author Information
1. Department of Internal Medicine, WHO Collaborating for Reference, Research on Viral Hepatitis, Korea. yoonsk@catholic.ac.kr, baesh@catholic.ac.kr
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
cyclophosphamide;
hepatocellular carcinoma;
metastasis;
metronomic chemotherapy
- MeSH:
Animals;
Antineoplastic Agents/*administration & dosage/*pharmacology;
Carcinoma, Hepatocellular/chemically induced/*drug therapy/mortality/pathology;
Cell Proliferation/drug effects;
Cyclophosphamide/*administration & dosage/*pharmacology;
Diethylnitrosamine;
Disease Models, Animal;
Gene Expression Regulation, Neoplastic/*drug effects;
Liver Cirrhosis/chemically induced;
Liver Neoplasms/chemically induced/*drug therapy/mortality/pathology;
Lung Neoplasms/drug therapy/pathology/secondary;
Male;
Matrix Metalloproteinases/metabolism;
Neovascularization, Pathologic/enzymology/physiopathology;
Rats;
Rats, Sprague-Dawley;
Survival Analysis;
Tissue Inhibitor of Metalloproteinases/metabolism;
Tumor Burden/drug effects
- From:Experimental & Molecular Medicine
2011;43(5):305-312
- CountryRepublic of Korea
- Language:English
-
Abstract:
Although continuous low-dose (metronomic [MET]) therapy exerts anti-cancer efficacy in various cancer models, the effect of long-term MET therapy for hepatocellular carcinoma (HCC) remains unknown. This study assessed the long-term efficacy of MET on suppression of tumor growth and spontaneous metastasis in a rat model of HCC induced by administration of diethylnitrosamine for 16 wk. The rats were divided into 3 groups: MTD group received intraperitoneal (i.p.) injections of 40 mg/kg cyclophosphamide on days 1, 3, and 5 of a 21-day cycle; Control and MET groups received i.p. injections of saline and 20 mg/kg cyclophosphamide twice a week, respectively. Anti-tumor and anti-angiogenic effects and anti-metastatic mechanisms including matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs (TIMPs) were evaluated. Twelve wk of MET therapy resulted in a significant reduction in intrahepatic tumors than control or MTD therapy. The MET group had fewer proliferating cell nuclear antigen-positive cells and decreased hypoxia-inducible factor-1alpha levels and microvessel density. Lung metastases were detected in 100%, 80%, and 42.9% in the control, MTD, and MET groups, respectively. MET therapy significantly decreased expression of TIMP-1, MMP-2 and -9. For mediators of pro-MMP-2 activation, MET therapy induced significant suppression in the TIMP-2 and MMP-14 level. The survival in the MET group was significantly prolonged compared to the control and MTD groups. Long-term MET scheduling suppresses tumor growth and metastasis via its potent anti-angiogenic properties and a decrease in MMPs and TIMPs activities. These results provide a rationale for long-term MET dosing in future clinical trials of HCC treatment.
